Kura Oncology at Jefferies Conference: Strategic Advancements in AML

Kura Oncology presented at the Jefferies Global Healthcare Conference 2025, highlighting promising Phase 2 data for Ziftomenib in AML, with a 23% complete response rate and median overall survival of 16.4 months. The company is financially stable with $703 million in cash and potential milestone payments of $375 million from Keogh Kirin, fully funding them through frontline commercialization; a Phase 3 trial is planned for the second half of the year, combining intensive chemotherapy and Venetoclax/Azacitidine regimens, aiming for broad label potential with a PDUFA date of November 30. Kura is also exploring market expansion beyond AML into solid tumors like GIST and breast cancer, with the total market size for frontline AML estimated between $5 billion and $10 billion.

Analysis

Kura Oncology (NASDAQ:KURA) presented compelling progress for its Menin inhibitor, Ziftomenib, in acute myeloid leukemia (AML) treatment at the Jefferies Global Healthcare Conference. Phase 2 data demonstrated a 23% complete response rate and a notable 16.4-month median overall survival for responders, a significant improvement over the typical three-month survival in relapsed/refractory AML. The company highlighted Ziftomenib's favorable safety and tolerability profile, including manageable differentiation syndrome, no clinically meaningful QT prolongation, and absence of myelosuppression, positioning it strongly for combination therapies. Financially, Kura is robust, holding $703 million in cash, with potential for an additional $375 million in milestone payments from Keogh Kirin, ensuring full funding through the AML program's frontline commercialization. Key upcoming catalysts include the PDUFA date for Ziftomenib set for November 30, under Priority Review with Breakthrough Therapy Designation, and the planned initiation of a consolidated Phase 3 trial in the second half of the year targeting a broad label across intensive chemotherapy and Venetoclax/Azacitidine regimens. The company aims to capture a significant portion, potentially $3 billion or more, of the estimated $5 billion to $10 billion frontline AML market. Beyond AML, Kura is strategically expanding Ziftomenib into solid tumors, evidenced by the initiated COMMOD-fifteen study in GIST, and is advancing its FTI program with data for Tipifarnib and KO-2806 anticipated in late 2024. Management expressed confidence that the FDA's stance on accelerated approval pathways using MRD negativity or complete response endpoints for AML remains unchanged, supporting their regulatory strategy.

Key Decisions for Investors

• Investors should monitor Kura Oncology's progress towards the November 30 PDUFA date for Ziftomenib and the initiation of its pivotal Phase 3 AML trial in H2 2025, as these are significant near-term catalysts.
• Consider the potential market share Ziftomenib could achieve in the $5-$10 billion frontline AML market, driven by its differentiated safety profile, once-daily oral dosing, and strong combinability, weighed against the competitive Menin inhibitor landscape.
• Evaluate the long-term growth prospects stemming from pipeline expansion, particularly data from the GIST program (COMMOD-fifteen) and the FTI program (Tipifarnib and KO-2806), which could provide upside beyond the core AML indication.
• Assess Kura's robust financial position, which fully funds AML commercialization, as a de-risking factor, while remaining cognizant of inherent clinical development and regulatory approval risks.